Investment implications as GLP-1s approach a new frontier [Video]

At the 2023 Livewire Live event, we made a bold, perhaps audacious, prediction: 2024 would mark the beginning of the end for obesity.

Normally, I prefer to keep my forecasts private until reality validates them, but the Livewire Shocking Predictions segment left no room for hedging. Amazingly, it seems that this prediction is coming to fruition.

For the first time in over 50 years, obesity rates in the U.S. have reached an inflection point and are trending downward.

The catalyst? The revolutionary GLP-1 class of drugs, poised to become the best-selling pharmaceuticals of all time by 2030, with an estimated $150 billion in annual sales.

The GLP-1 drugs, initially developed by Novo Nordisk (Ozempic) and later joined by Eli Lilly (Mounjaro), have demonstrated efficacy across a range of conditions – from obesity and diabetes to heart disease, Alzheimer’s, and arthritis. Dubbed the “Swiss Army knives” of modern medicine, these drugs are transforming healthcare.

Could GLP-1s treat other …